Mouse, dish or human? Semaglutide extended lifespan in old female mice by 92 days.

A paper in Nature today, with a same-day release from the National Institutes of Health, reports that semaglutide — the molecule in Wegovy — given to female mice from 20 months of age extended their median lifespan from 742 days to 834, about 12%. Treated mice ate 24% less, and a comparison group fed 24% fewer calories did not do as well on memory, exploration and glucose control, which suggests the drug did something beyond restricting food. The lifespan cohort was 40 treated mice and 39 controls. The NIH's own release says the findings do not show that similar results would occur soon in humans. By Friday the marketing will say otherwise, so here is the full answer to our standing question.

Mouse. Female, one strain, started old, one dose, one lab, with a modest group size; male mice were not studied. The result is interesting and NIH-funded, and it belongs to a literature in which many things extend mouse lifespan — calorie restriction, rapamycin, metformin in some strains and not others — and almost none has been shown to extend human life. The human evidence on this molecule is different in kind: a 17,604-person trial showing fewer heart attacks and strokes in people with obesity and existing cardiovascular disease, and a year of weight-regain data after stopping. That is a drug for a disease, not a longevity intervention for the healthy, and a mouse paper does not change the category.

Loree’s take

I expect to be asked this month whether a healthy 55-year-old should take a GLP-1 to live longer. The answer is the same as before the mice: there is no human evidence for that use, the side effects are real and the weight returns when the drug stops. The mice are a reason for researchers to run a human study. They are not a reason for a patient to start a prescription, and a clinician who suggests they are is reading the wrong species.

Ben’s take

This is the most valuable molecule in medicine, and it just got a lifespan headline. Every channel that sells it — telehealth, compounders, clinics — has an incentive to let "in mice" fall off the sentence, and the sentence without it is worth billions. Watch for it. When you see "semaglutide extends lifespan" without the species, you are looking at the longevity trap built in real time.

Why it matters to a recovering optimizer. The mouse result is a good one and it is a mouse result. The things that extended lifespan in people in the studies we trust — moving, sleeping, eating real food, having people — have no mouse-to-human gap to cross, because they were measured in humans. When the human trial of this drug in healthy older adults is run, we will write about it. Until then, the species is the headline.

This post reports on evidence and expert disagreement. It is not medical advice; decisions about treatment belong with you and your clinician.